This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by O'Neill, W. W. Articles by O'Neill, B. P. Search for Related Content PubMed Articles by O'Neill, W. W. Articles by O'Neill, B. P. Related Collections Related Article

Editorials

The First Generation of Angioplasty

William W. O'Neill, MD and Brian P. O'Neill, MD

From the Office of the Executive Dean for Clinical Affairs, Miller School of Medicine, University of Miami, Miami, Fla.

Correspondence to William W. O'Neill, MD, Office of the Executive Dean for Clinical Affairs, Miller School of Medicine, PO Box 016960 (R-696), University of Miami, Miami, FL 33101. E-mail woneill@med.miami.edu

Key Words: Editorials

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Merriam Webster defines a human generation as the time from the birth of parents to that of their offspring. Typically, that time is 20 to 30 years. Thus, it has been 1 human generation from Andreas Gruntzig’s original description of balloon angioplasty in 1978 to its 30th anniversary in 2008.¹ Three months after this report, one of us (B.P.O.) was born to a father (W.W.O.) who was starting his career in cardiac medicine. Thus, 2008 for us is a year of transition of a cardiac interventionalist from one generation to the next. At this time, it is fitting to reflect on the people, the procedure, and the practice in the first generation of angioplasty. In this issue of Circulation: Cardiovascular Interventions, Venkitachalam et al² provide an overview of the changes that have occurred in practice and outcomes of the 1985–1986 National Heart, Lung, and Blood Institute (NHLBI) Registry and the NHLBI Dynamic Registry. The report highlights the remarkable distance we have covered with this procedure in a generation.

Article see p 6

Imagine for a moment that you were a young investigator in 2008 and had invented a new device to treat coronary occlusions. You need to obtain millions of dollars in start-up funding and get institutional review board and Food and Drug Administration approval to initiate US clinical trials. The device is designed to treat young patients with stable angina, single-vessel disease, focal, concentric proximal lesions, and normal left ventricular function. The device has to be inserted through . . . [Full Text of this Article]

Related Article

Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on Clinical Outcomes: A Report From the National Heart, Lung, and Blood Institute–Sponsored, Multicenter 1985–1986 PTCA and 1997–2006 Dynamic Registries

Lakshmi Venkitachalam, Kevin E. Kip, Faith Selzer, Robert L. Wilensky, James Slater, Suresh R. Mulukutla, Oscar C. Marroquin, Peter C. Block, David O. Williams, Sheryl F. Kelsey for the Investigators of NHLBI-Sponsored 1985–1986 PTCA and 1997–2006 Dynamic Registries
Circ Cardiovasc Interv 2009 2: 6-13. [Abstract] [Full Text] [PDF]